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Reviewy of Type 2 diabetes (CNDM2) has not been positively deﬁned. This review
includes a description of CNDM2 research from before the ‘Pubmed Era’. Recent neuroimaging studies have
focused on cerebrovascular and white matter pathology. These and prior studies about cerebrovascular
histopathology in diabetes are reviewed. Evidence is also described for and against the link between CNDM2
and Alzheimer's disease pathogenesis. To study this matter directly, we evaluated data from University of
Kentucky Alzheimer's Disease Center (UK ADC) patients recruited while non-demented and followed
longitudinally. Of patients who had come to autopsy (N=234), 139 met inclusion criteria. These patients
provided the basis for comparing the prevalence of pathological and clinical indices between well-
characterized cases with (N=50) or without (N=89) the premortem diagnosis of diabetes. In diabetics,
cerebrovascular pathology was more frequent and Alzheimer-type pathology was less frequent than in non-
diabetics. Finally, a series of photomicrographs demonstrates histopathological features (including clinical–
radiographical correlation) observed in brains of persons that died after a history of diabetes. These
preliminary, correlative, and descriptive studies may help develop new hypotheses about CNDM2. We
conclude that more work should be performed on human material in the context of CNDM2.
© 2008 Published by Elsevier B.V.1. Introduction
More than 90% of diabetes mellitus cases in Western countries
correspond to Type 2 diabetes (“non-insulin dependent”, or DM2) [1].
Although technically a misnomer, the term “diabetes” is used herein to
encompass clinical signs and symptoms relating to DM2. The central
focus of this review is the cerebral neuropathology of DM2 (CNDM2).
We will review brieﬂy the scientiﬁc literature from studies in
epidemiology, neuropsychology, neuroimaging, and histopathology
research that are relevant to human CNDM2. Correlative and descriptive
data will be analyzed from the University of Kentucky Alzheimer's
Disease Center (UK ADC) autopsy cohort. These studies include a case–
control series depicting clinical and pathological indices stratiﬁed by the
antemortem diagnosis of diabetes. Our study also includes a series of
photomicrographs from diabetics' brains that help depict some of the
vascular and white matter changes along with radiographical–neuro-
pathological correlation. A central conclusion is that direct pathological3 and K08 NS050110 from the
m theHealy Family Foundation.
Division of Neuropathology,
n Building, 800 S. Limestone,
. Tel.: +1 859 257 1412 x 254;
lsevier B.V.studies of human tissues, despite all their technical challenges, are an
important experimental component to the study of CNDM2.
2. Potential confounds
Prior studies have been unable to demonstrate pathognomonic
changes that discriminate the brains of humans with diabetes from
“non-diabetic” brains. This may reﬂect the formidable obstacles or
potential confounds in studying diabetic brain disease. Below we
describe ﬁve of the most important potential confounds relevant to
research on DM2 and the human brain.
2.1. Cohort effect, case–control pitfalls, and other potential biases
In a historical sense, “diabetes” is a moving target. New treatments
emerge each year. Environmental challenges, including dietary
changes [2] and medications for other diseases, evolve also. These
produce changes that impact entire generations and may affect
different groups or cohorts distinctly. Thus, there is no guarantee that
a human study performed in 2008will be relevant directly to diabetics
in 2028. Another problem is that in any “case–control” study, most
individuals identiﬁed as diabetics will have been treated for diabetes,
whereas some that were not identiﬁed as diabetics will be in fact
untreated diabetics. This potential confound can be minimized by
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ever, in a study with rigorous clinical documentation and careful case
selection, the diabetics may be even better controlled in their medical
and diet regimens and their case–control outcome differences may
change commensurately. Age effects are also difﬁcult to determine
without rigorous controls—the ﬁndings of the effects of hyperglyce-
mia on brain tissue in a 30-year old are impossible to project onto
those in an 80-year old.
2.2. Distinct group characteristics—comorbidities, environmental factors,
and genetic factors
DM2 cases are nonrandomly distributed in populations. Rather, the
disease is associated strongly with indices related to medical
comorbidities, socioeconomic factors, and genetic factors. Many
studies on diabetics have noted systematic abnormalities in blood
pressure, atherosclerosis, and blood values for pH, urate, lipids,
ketones, and clotting factors [3–7]. Diabetics also tend to have
concomitant environmental risks such as obesity (presumably
reﬂecting an altered diet) and smoking [1,2,8,9]. Other potential
confounds in diabetes studies are the socioeconomic factors that may
induce case-versus-control systematic biases in patients' trust of, and
willingness to participate in, clinical trials [10–12] much less autopsy-
based research. Finally, there are hypothesized genetic risk factors that
may relate both to themetabolic syndrome and to neurodegeneration,
such as the apolipoprotein E allele [13–17]. In summary, it is a
challenge to detect whether a brain change is speciﬁc to CNDM2 –
hyperglycemia and/or insulin resistance per se – rather than a
combination of other medical, environmental, and genetic factors,
that disproportionately accompany CNDM2. This consideration
amounts to multiple potential confounds that are extremely challen-
ging to eliminate completely, irrespective of study design.
2.3. Hypoglycemia and other treatment effects
Insulin or other agents can induce hypoglycemia iatrogenically.
Hypoglycemia induces seizures, coma, and widespread cerebral
cortical neuronal loss when glucose levels fall below ~1–1. 5 mM
(18–27 mg/dl) [18–24]. The neuropathology that is associated with
this devastating condition is not identical to that of widespread
ischemia or hypoxia [23,24]. The mechanism of this special type of
neuropathology is apparently excitotoxicity via the neurotransmitter
aspartate [23,24]. More relevant to many diabetics are the effects of
episodic, short stretches of hypoglycemia, aggravated perhaps by
chronic recurrence with cycles of hyperglycemia and/or respiratory
depression [25]. Depending on many factors, the net effects may be
subtle and idiosyncratic. In human studies, teasing out the speciﬁc
importance of hypoglycemia, versus hyperglycemia, is not a trivial
challenge. Further, hypoglycemic agents have effects on the brain
other than those that are involved in glucose regulation [26,27].
Medicinal preparations intended to lower blood glucose differentially
affect albumin binding, inﬂammation, blood-brain transport, and
other brain and liver indices [26–29]. Additional treatment effects
may also be important. Most diabetics take many drugs concomi-
tantly, many of which relate to metabolism, electrolytes, lipids,
platelets, hormones, immunomodulation, and/or blood pressure. For
example, in the data presented below, the diabetic patients (N=50,
average age at death, 84 years) had an average intake of over 12
different medications daily. The biological effects of these drugs, in
isolation or together, may alter observed brain pathology.
2.4. Glucose—one sugar, many pathways, and complicated curves
Most organisms use glucose as a transportable energy source.
Glucose is also a moiety that can be attached – enzymatically or non-
enzymatically – to proteins, nucleic acids, and lipids [30–32]. Highlyamenable to molecular modiﬁcations itself, glucose is a potential
“player” in many biochemical pathways [30]. Exactly how these
pathways are stimulated and inhibited in vivo is currently poorly
understood; there is still debate about the basic fundamentals of
cellular glucose metabolism in the brain [33–37]. The brain glucose
and insulin pathways involve complicated, interacting ripples of
effects and counter-effects. The impact on blood vessels by hypergly-
cemia is thought to be partly mediated through the polyol sorbitol
pathway, myo-inositol depletion, diacylglycerol pathway, platelet
regulation, and many others [18,20,38–49]. Furthermore, cardiovas-
cular factors can have complicated and non-linear dynamics. For
example, in compelling mammalian models of cerebral infarction,
hyperglycemia can be either neuroprotective, or by contrast neuro-
toxic, depending on the model parameters [50–54]. An additional
example of complex non-linear cerebrovascular dynamics in humans
is the well-documented but unexplained epidemiological “J-shaped
curve” effect of alcohol intake upon stroke risk [55–61]. Given these
considerations, data can be difﬁcult to extrapolate from an experi-
mental model to the human brain. For example, how can we know if
the effects of hyperglycemia at blood levels of 100 mg/dl, 200 mg/dl,
and 300 mg/dl on a given brain cell parameter are linear, exponential,
or opposite from each other?
2.5. Pitfalls of animal models and comparative disease-related
neurobiology
Historically, diabetes research provides outstanding examples of how
animal models can be used to inform and improve treatment of human
diseases [62,63]. In the context of CNDM2, a number of hypotheses have
been developed and tested based largely on animal models [64–70]. On
the other hand, there are also drawbacks in using animals to model
human cognition and human-speciﬁc pathology. Because there is not a
known, speciﬁc cerebral pathological substrate for diabetes in humans, it
is instructive to review the experience in animal models of diabetic
kidney disease. A pathognomonic diabetic nephropathy lesion is known,
so a mouse model should theoretically help to understand the disease
mechanisms and work toward a cure. Unfortunately, although kidney
failure is commonplace in humans [71–73], this change has been
extremely difﬁcult to reproduce in mouse diabetes models [74,75].
There is considerable mouse strain-speciﬁc variation in diabetes-related
nephropathy [74,75]. Commonly used strains such as C57BL/6 are almost
entirely resistant todiabetic changes in thekidney, and in fact less than5%
of mouse strains have reported such pathology [74,75].
What about rodentmodels of human brain disease in diabetes? The
human brain is unique, and there are crucial differences between
rodent and human aging trajectories. As such it is not surprising that
rodent models of CNDM2 have shortcomings [68,76]. Transgenic or
treated rodents have been unable to model the best-established
substrate for cognitive loss in diabetic humans, namely atherogenic
cerebrovascular changes [64,68,76]. Models of other diabetes-related
changes on cognition also have varied results. These studies are
compounded by the challenges to test subtypes of cognitive domains
in rodents. Some diabetes-related studies have produced no cognitive
changes in the presence of hyperglycemia, and others show abnorm-
alities in rodent cognitive/behavioral indices even without hypergly-
cemia [64]. Furthermore, the perturbations that accompany diabetes
studies in animals bear consideration. For example, intracerebral or
intraperitoneal injection of streptozotocin (SZT) leads to pathological
changes analogous to Alzheimer's disease (AD), namely increased
phosphorylated tau [69,77–81]. It should be borne inmind that SZThas
direct CNS toxicity beyond the known effects of diabetes per se [82–
84], and some of the effect of SZT on tau proteins is mediated through
hypothermia [69]. The animal studies are biologically interesting and
may prove their relevance to humans. However, reciprocal validation is
important because animal research and human studies have both
complementary strengths as well as complementary weaknesses.
Fig. 1. There are no neuroimaging ﬁndings entirely speciﬁc to diabetes per se, i.e. effects
of hyperglycemia. Shown is an axial FLAIR image from a 67-year old diabetic man. It
shows typical periventricular hyperintensities (“WMLs”) seen with diabetes (arrow).
These lesions are compounded by other factors: age, hypertension, hypercholester-
olemia, and homocysteinemia. In a meta-analysis of MRI ﬁndings linked to diabetes,
population studies found an odds ratio of ~2 for MRI-detected WMLs in diabetes.
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Due partly to the challenges described above, there has been some
variability in the results of studies about changes in cognition linked
to diabetes. The neurological dysfunction associated with this disease
has been designated “diabetic encephalopathy” [45,85,86], yet this
term has not been rigorously deﬁned by a consensus of experts.
Speciﬁc cognitive disturbances associated with diabetes have been
described (for reviews see [5,17,46,87–90]). Deﬁcits have been
repeatedly observed in particular cognitive domains, including
memory and psychomotor speed [46,91]. There is some overlap
between the ﬁndings of cognitive changes in DM1 and DM2
[43,46,92–94] and an increased risk for dementia or mild cognitive
impairment in DM2 and some of this literature is described below.
Research about cognitive changes in diabetics demonstrates the
importance of study design. Many experiments assessing the effects of
diabetes on cognition and/or pathology (including the research
described below) have employed a case–control research design.
This study format has important advantages in that cases and controls
can be carefully monitored, compared, and described; however, these
studies are prone to selection and recruitment biases. A study design
involving fewer such biases is a population-based study. These studies
typically have more patients and are more representative of a large
and heterogeneous cohort. Almost one-half of the published popula-
tion studies have been interpreted to show no effect of diabetes on
cognition [17]. However, these results also may have methodological
problems including difﬁculty with accurate identiﬁcation of cases and
controls.
Future studies may overcome the many confounds and discrimi-
nate in ﬁne details which speciﬁc aspects of DM2 correspond towhich
subdomains of cognitive dysfunction. In the meantime, the literature
on the cognitive deﬁcits related to diabetic encephalopathy produces a
general consensus that multiple cognitive domains are affected
adversely in diabetics. There is general, but by no means universal,
agreement about “direction of effect”—hyperglycemia is associated
with mild cognitive dysfunction in many studies. However, there is
uncertainty about the precise relationships to biological mechanisms.
Thus, speciﬁc aspects of prior studies should be interpreted with
critical scrutiny.
4. Recent neuroimaging studies related to diabetes-linked
anatomic and cognitive changes
To the extent that diabetes can be documented to affect cognition,
neuroimaging can correlate structural brain parameters with cogni-
tive changes. Unlike neuropathological studies, brain scans can be
used to monitor quantitatively the three dimensional effects of a
disease over time in an individual. Further, MRIs can assess
neuroanatomical areas suspected of involvement in the diabetic
brain, namely the cerebrovascular and white matter disease, which
are problematic to study routinely in the context of tissue-based
neuropathology. For these reasons, neuroimaging studies are practi-
cally tailor-made to surmount many of the obstacles in assessing the
cerebral neuropathology of diabetes.
Van Harten et al. (2006) provided an outstanding meta-analysis
summarizing critically the literature on neuroimaging of diabetes [95].
This study included formal analysis of 46 studies (including popula-
tion-based, case–control, and clinical studieswith various vascular risk
factors) usingMRI and/or CT. All of these included at least 20 diabetics
with speciﬁed criteria for diabetes. According to thismeta-analysis, the
following three structural changes are described consistently in the
brains of diabetic patients:
1. White matter lesions (WMLs; 27 studies analyzed) — Some but not
all studies showapositive correlation between thepresence ofWMLs
and DM2. When studying cohorts with many vascular risk factors inaddition to diabetes, there were weak or no correlations between
diabetes and WMLs. In outpatient case–control studies, there was a
weak association between WMLs and DM2. A typical depiction of
WMLs in the brain of a diabetic is shown (Fig. 1).
2. Lacunar infarcts (LIs; 20 studies analyzed) — A signiﬁcant
association was found between the presence of lacunar infarcts
and DM2 across different study designs.
3. Cortical atrophy (CA; 10 studies analyzed) — Studies assessing
cortical atrophy were too heterogeneous methodologically to
summarize; however, nine of the ten publications in the meta-
analysis showed a positive correlation.
Studies performed since the meta-analysis of Van Harten (2006)
have further explored the correlation of radiographical changes with
the severity of cognitive dysfunction in diabetics [90,93,96–100]. The
results of some of these studies are shown in Table 1. Note that the
importance and speciﬁcity of WMLs appears to be more accentuated
in these later studies. Thus, neuroimaging studies help to focus the
questionwith some hope of success, by showing that there are speciﬁc
anatomical substrates for the cognitive decline seen in diabetics:
WMLs, LIs, and CA. Of these three, the two least well understood are
WMLs and CA. In the future, technology that probes both functional
and structural parameters (fMRI) should provide further insights into
diabetes-related brain changes.
5. Human cerebral neuropathology of diabetes
Histopathological studies may complement epidemiological, neu-
ropsychological, and neuroradiographical research regarding the
effects of diabetes in the human brain. The discovery of a speciﬁc
anatomical substrate for CNDM2 would provide needed traction for
other experimental systems and for developing therapies. Human
CNDM2 data will be described in subsections: ﬁrst, an overview of
Table 1
Recent MRI studies that correlate anatomical changes with cognitive dysfunction
Ref. Patients MRI ﬁndings in association
with Type 2 diabetes
Notes
[98] 113 DM2 WMLs, cortical and subcortical
atrophy are associated with
cognitive decline
Cognitive dysfunction
correlated to WMLs and brain
atrophy. A1C was 6.9%
(moderately well-controlled)
51 controls
[96] 122 DM2 WMLs, atrophy are associated
with cognitive decline;
pathology and other factors
show interactions
Cognitive dysfunction
correlated with WMLs, atrophy,
hypertension,
hyperinsulinemia, and “vascular
events”; statin use was
associated with improved
WMLs and with improved
cognition
56 controls
[90] 92 DM2 PVH, WMLs, lacunar infarcts,
and cerebral atrophy observed;
only PVH was associated with
“motor slowing”
MRI ﬁndings less well
associated with cognitive
dysfunction in relation to
HbA1C and duration of diabetes,
which showed stronger
correlation with cognitive
dysfunction
44 controls
[93] 40 DM1 DM2 patients have more WMLs
and cortical atrophy in
comparison to DM1 patients
with much longer disease
duration
DM2 patients had more
cognitive dysfunction but also
more of other metabolic aspects
including more hypertension,
lipid disorders, etc.
40 DM2
[97] 122 DM2 WMLs, atrophy, which were not
correlated with peripheral
neuropathy within given
patients
Authors conclude that CNS and
PNS pathology of DM2 may be
unrelated because of
discrepancies within
individuals
56 controls
[100] 95 DM2 “White matter hyperintensities”
in various areas correlated with
declines in cognitive domains
Memory and “mental speed”
deﬁcits were associated most
strongly with white matter
hyperintensities in parietal lobe
and thalamus
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review of the literature concerning speciﬁcally whether or not
diabetes is linked to AD pathology; second, studies from the UK ADC
autopsy cohort include a case–control study on material from the UK
ADC Brain Bank to describe our experiences regarding neuropatho-
logical ﬁndings in the brains of diabetics, with a series of photo-
micrographs to demonstrate ﬁndings in diabetics' brains including
radiographical–pathological correlations; and ﬁnally, a summary and
conclusions.
6. Peripheral and autonomic nervous system pathology of
diabetes
Details about the manifestations of diabetes in the peripheral and
autonomic nervous systems are outside the scope of this review.
Brieﬂy, peripheral and autonomic neuropathic changes are prevalent,
occurring in ~15–25% of diabetic patients [101–107]. Hyperglycemia
itself is the main risk factor [103,104]. The often painful “glove and
stocking” (long-ﬁber) sensorimotor polyneuropathy is the most
common neuropathic syndrome in Western countries [105,106].
Autonomic neuropathy is selective but affects many systems, and
cranial neuropathy (worst in the oculomotor nerve) is also quite
prevalent [108,109]. The histopathology for these changes is
relatively nonspeciﬁc. Nerves show demyelination and remyelination,
a dropout of small and large axons, impaired axonal regeneration,
Schwann cell dropout, and/or neuritic dystrophy, often with nearby
microangiopathy [104,109–117]. The pathological changes may be
caused or exacerbated by the polyol sorbital pathways, glycation
reactions, oxidative/inﬂammatory mechanisms, and other pathways
[109,110,118–120]. The prevalent but unspeciﬁc peripheral nervoussystem diabetes-related pathology may be relevant biologically to
changes in the brain. However, those who have carefully evaluated
both in parallel have found the brain pathology far more difﬁcult to
discern [85] and/or often disproportionate in degree with the PNS
pathology in individual patients [97].
Ultimately, the conclusions from the Pathology of Diabetes, 4th
Edition (1966) still holds true: “there is still no agreement on the
pathogenesis or basic mechanism of diabetic peripheral neuropathy”
(p.273) [121].
7. Histopathology of diabetes in the brain: literature review
7.1. Historical note
Much of the work on diabetes pathology dates from before the
advent of the ‘Pubmed Era’. Naturally, these “classical” studies could
only localize diabetes-related brain changes using techniques that
are somewhat crude by modern standards. However, it is signiﬁcant
that highly observant researchers, superbly trained in anatomic
pathology, and in an era with widespread un-controlled diabetes,
could ﬁnd meager evidence of speciﬁc changes in the brains of
diabetics.
In the Pathology of Diabetes, 4th Edition (1966) [121], the authors
designate a chapter to the CNS pathology of diabetes. Here are some
relevant excerpts:
“From the brains which we have examined, and from the reports
in the literature, there are no changes distinctive of diabetes other
than the abnormal glycogen deposits reported in certain cases of
diabetic coma...” [121] (p. 279) “…ﬁndings of Vonderahe [122]
and of Morgan et al. [123] of a reduced number of ganglion cells in
the paraventricular regions have not been conﬁrmed...Hagen [124]
has described granular inclusions in nerve cells of the hypotha-
lamic region...” [121] (p.280)
Throughout the human body, according to these authors, diabetes
affects all blood vessels from the largest to the smallest. However,
special focus was merited for arterioles and capillaries:
“Ever since the distinguished studies of Bell [125–127] it has been
recognized that arteriolosclerosis is likely to be more severe and
extensive in the diabetic, even in the absence of hypertension.”
[121] (p.313) “The capillaries have frequently been regarded as the
site of ‘diabetic microangiopathy’, largely because of the impor-
tance attributed to the nodular glomerular lesion of Kimmelsteil
and Wilson as the one speciﬁc lesion of diabetes and the
popularity of the common, though nonspeciﬁc micro-aneurysms
of the retinal capillaries.” [121] (p.317)
In the speciﬁc context of brain disease, “minor changes are difﬁcult to
evaluate since a number follow vascular damage and vascular change
is very frequent in the diabetic...” [121] (p.280). Forty-two years after
this ﬁnal edition of The Pathology of Diabetes, pathologists still only
appreciate two relatively speciﬁc diabetes-related lesions outside the
pancreas—Kimmelstiel–Wilson nodules in the kidney and diabetic
retinopathy (Fig. 2).
7.2. Recent work on cerebral neuropathology of DM2
With regard to more recent ‘conventional’ cerebral histopatholo-
gical studies, the scientiﬁc literature on diabetes/hyperglycemia in
human brains has been nearly mute for several decades. A survey of
four popular, comprehensive clinical atlases on neuropathology [85,
128–130] provides little information about diabetes-related pathol-
ogy. Only the Textbook in Neuropathology, 3rd Ed (Davis and Robertson
Eds, 1997) [85] has a section dedicated to describing the histopathol-
ogy of diabetic encephalopathy. This section begins: “Most clinicians
Fig. 2. Universally recognized diabetes-related histopathology outside the brain is
referent to vascular complications in the kidney and eye. Because of prior studies,
these lesions are “pathognomonic” in the sense of indicating diabetes in a patient
independent of whether or not the clinical history is well-documented. Diabetic
nephropathy involves glomerular vascular lesions termed Kimmelstiel–Wilson
nodules (arrow in A). Thin-walled blood vessels in the roughly-spherical
glomerulus comprise the anatomical substrate for plasma ﬁltration. With diabetes
over a decade in duration, a nodular glomerulosclerosis may develop heralded by
albuminuria that can lead to kidney failure. Diabetic retinopathy (B and C) is
evaluated using fundus microscopy (fundus indicated by an “f”). The pathology can
be parsed into two subtypes: non-proliferative (B) and proliferative (C) retino-
pathy. Non-proliferative changes (B) are less severe with small capillary micro-
aneurysms, dot-type hemorrhages, and microinfarcts (“cotton-wool” spots). This
change is associated with gradual but generalized visual dysfunction. Proliferative
changes (C) involve neovascularization, ﬁbrosis, and hemorrhages, which can be
extensive. Sudden vision loss can occur with vitreous hemorrhage and/or retinal
detachment.
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cerebrovascular disease.” [85] (p.590).
The same neuropathology atlas [85] goes on to enumerate several
other histopathological ﬁndings associated with diabetic encephalo-pathy: thickening of cerebral cortical capillary basement membrane;
possible abnormality in blood-brain barrier; diffuse degeneration of
“ganglion cells” and nerve ﬁbers throughout the brain (attributed to
Reske-Nielsen and Lundbaek [86]) or diffuse degeneration of cortical
neurons similar to those seen in anoxia and ischemia (attributed to
Olsson et al. [131]), with poor correlation to hypertension or uremia.
Since these are the only authors with a relatively recent summary of
the human neuropathology of diabetic encephalopathy, it is worth
quoting their conclusions—.
“Although it is conceivable that the primary ganglion cell
abnormalities in diabetic encephalopathy may be related to
microangiopathy and increased vascular permeability, many
aspects in its pathogenesis are still unknown.” [85] (p.591)
In addition to neuropathology atlases, there have been individual
studies about the pathology in diabetics' brains. Some autopsy series
have included evaluations of cerebral pathology in relation to diabetes
[86,132–138]; however, there have been few such studies published
during the past several decades. Hypothesis-based studies have
sought to conﬁrm in human tissues features seen in animal or other
models [139–141]. Various ﬁndings have been reported, none
deﬁnitive, except that there is a positive association between diabetes
and various strokes [88,132,142–144]. Of the issues pertinent to brain
pathology in diabetes that have received most attention, two are
conspicuous: the role of cerebrovascular diseases in diabetics, and the
pathogenetic connection to AD.
Relatively few recent studies have described in detail the
cerebrovascular histopathology linked to diabetes. The scarcity of
recent studies stands in contrast to the impressive epidemiological
and neuroimaging evidence indicating that diabetic brain dys-
function is mediated at least partly via cerebrovascular disease
[88,90,98,132,142–145] (and see below). The lack of human histo-
pathological studies is also remarkable since there are few animal
models of diabetes-linked atheromatous brain infarcts [76]. Further-
more, there is cause to re-examine the older autopsy series, because in
one study more than a third of patients with cerebral infarcts had an
elevated glycosylated hemoglobin although they were not known
previously to be diabetics [146,147]. There have been few large human
autopsy series performed since that of Aronson (1973) [136]. This
study included 4802 non-diabetics and 677 diabetics from consecu-
tive, complete autopsies performed at Kings County Hospital in
Providence, RI. In this study, the frequency of encephalomalacia –
softening of the brain, oftenwith rarefaction of white matter –was far
more frequent in the diabetics. The author concluded that this
pathology reﬂected small-vessel disease that was “presumably not
lethal and frequently subclinical, which is distinctly greater” in
diabetics [136]. The correlation of diabetes with small-vessel disease
is important and has been repeatedly described [90,96,99,148,149].
This type of pathology is associated with clinical manifestations in
sharp contrast to the “stroke” syndromes that are characterized by
acute, catastrophic neurological deﬁcits that often culminate in severe
disability or death. Instead, the neurological deﬁcits referent to small-
vessel disease can be subtle but progressive over time [150,151]. The
exact mechanisms that underlie small-vessel disease are not well
understood.
Although diabetes is most speciﬁcally linked to small-vessel
disease, it should be underscored that a connection is also ﬁrmly
established between diabetes and other subtypes of cerebrovascular
disease [6,132,145,152–157]. This pertains to large vessel athero-
sclerosis, lacunar infarcts, thromboembolic stroke, hemorrhagic
stroke, and aneurismal subarachnoid infarcts [15,158–167], all of
which can produce a spectrum of clinical syndromes. The relative risk
for clinically detectable stroke overall in diabetics is in the range of 1.7
to 5.5 (see review in ref. [146]). This is a devastating disease with an
incidence of ~760,000/year in the U.S. [168–170], and it is estimated
Table 2
UK ADC: demographics and clinical indices
Diabetics Non-diabetics p-value
Demographics
N 50 89 –
Age at death, yrs (mean±SD) 84.7±8.0 88.2±6.7 b0.011
Sex (%F) 54 63 NS2
Formal education, yrs (mean±SD) 15.6±2.6 16.0±2.0 NS1
ApoE alleles (2/3/4), % 4/84/12 11/76/13 NS3
Last MMSE score (mean±SD) 26.4±5.1 24.4±7.4 NS1
Interval between last evaluation and
death, yrs (mean±SD)
0.64 0.96 NS1
Clinical parameters
Depression, % 20 20 NS2
CABG, % 14 7 NS3
Peripheral vascular disease, % 26 15 NS2
TIA, % 14 8 NS2
Hypertension, % 64 55 NS2
Daily intake of drugs/meds (mean±SD) 12.2±7.7 19.8±8.5 b0.00011
The demographic and clinical characteristics between diabetics (N=50) and non-
diabetics (N=89) in the BRAiNS program at the UK ADC. This group, which was
recruited from non-demented individuals, has been described previously [245]. The
demographic and clinical indices are similar between diabetics and non-diabetics. The
clinical parameters were dichotomous (0 or 1) except for “Number of drugs” (range: 2–
39). Deﬁnitions: ApoE = Apolipoprotein E; MMSE = Mini-mental status examination
(0–30 scale); CABG= coronary artery bypass graft operation; TIA= history of transient
ischemic attack(s). Statistical tests: Two-tailed Student's t test (1), Chi-square (2), or
Fisher's exact test (3).
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year [169]. Any additional hypotheses about the effects of DM2 on
cognition must include the much higher cerebrovascular risk in
diabetics as a scientiﬁc fact. If additional types of pathological or
clinical manifestations are to be suggested, then diabetes-relatedTable 3
UK ADC: pathological indices
Diabetics Non-diabetics p-value
Pathological parameters, non-Alzheimer's type
Lacunar infarcts, % 14 7 NS2
Micro-infarcts, % 52 30 0.012
Large infarcts, % 2 10 NS2
Hemorrhagic infarcts, % 8 4 NS2
Any infarcts, % 56 37 0.032
Hippocampal sclerosis, % 9 6 NS2
Argyrophilic grains, % 22 26 NS2
Lewy bodies in isocortex, % 6 11 NS2
Brain wgt, g (mean±SD) 1196±134 1193±139 NS1
Pathological parameters, Alzheimer's type
Braak stage (median, range) 2 (0–6) 3 (0–6) NS3
CERAD score (median, range) 0 (0–3) 2 (0–3) 0.023
NIARI score (median, range) 0 (0–3) 1 (0–3) 0.033
Probable or deﬁnite AD, % 24 22 NS2
NFT counts (mean±SD)
Temporal lobe 1.9±4.62 3.4±8.8 NS1
Frontal lobe 0.6±1.9 1.3±3.4 NS1
Parietal lobe 0.8±2.3 1.8±4.8 NS1
Hippocampal CA1 9.5±15.2 12.1±21.4 NS1
Subiculum 10.9±16.8 25.3±40.0 0.0041
Neuritic plaque counts (mean±SD)
Temporal lobe 3.9±5.9 6.4±7.4 0.041
Frontal lobe 4.6±6.9 6.6±7.3 NS1
Parietal lobe 5.3±7.6 7.5±8.3 NS1
Hippocampal CA1 1.5±3.0 1.1±2.4 NS1
Subiculum 1.9±3.9 1.9±3.6 NS1
Pathological indices stratiﬁed by diabetics (N=50) and non-diabetics (N=89) in the
BRAiNS program at the UK ADC. Note that small infarcts tended to be present more
often in diabetics, but AD-related pathology tended to be slightly more abundant in
non-diabetics.
Statistical tests: Two-tailed Student's t test (1), Chi-square (2), orWilcoxon Rank Sum (3).cerebrovascular disease is also a strong potential experimental
confound.
In contrast to the literature concerning cerebrovascular pathology
related to diabetes, the association of DM2 with AD pathology is more
controversial but has attracted intense scientiﬁc attention [171]. This
topic is challenging to address from a neutral perspective because the
results of the studies are mixed and sometimes seem mutually
contradictory. We describe below some of the data and hypotheses –
both “pro” and “con”– pertaining to the possibility that AD is
pathogenetically linked to DM2.
7.2.1. Data/hypotheses that suggest that AD is linked speciﬁcally to DM2
1. Numerous epidemiological and clinical–pathological studies have
reported an increased risk in DM2 patients for developing AD,
possibly in connection with ApoE allele 4 [16,154,172–180].
2. Neuroimaging studies show shrinkage of mesial temporal structures
(hippocampus and amygdala) in DM2 patients linked to loss of
cognition; these are also areas affected by AD [91,181–183].
3. The diabetic pancreas contains amyloid substance, similar histo-
logically to that found in AD brain [184,185].
4. There are inter-related pathways linked to the metabolic
syndrome and to dyslipidemia (including cholesterol transport
and ApoE alleles) that may credibly affect both DM2 and AD
[15,183,186–189].Fig. 3. Control Case 1 (A) shows normal appearance of small arteries in white matter
(arrows). Surrounding the blood vessels, partly as an artifact of ﬁxation, is a spacewithout
cells or parenchyma (Virchow–Robin space). Scale bar=150 μm. (B) in some cases, such
as this person (Diabetes Case 1, an 88-year old male with mild cognitive impairment), the
Virchow–Robin space is enlarged. The lumen of the blood vessel is shownwith a green “⁎”.
Note that in the Virchow–Robin space are extra blood vessels, and the tissue surrounding
has many corpora amylacea (arrow). Scale bar=100 μm.
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deﬁcits even in young adults at risk for developing AD decades
later (ﬁnding not linked to DM2 per se) [190–193].
6. AD is linked to hyperglycemia by the hypothesized importance
of insulin/IGF-1 regulated pathways, RAGE, PPAR-gamma, and
other advanced glycation end-products in AD brain
[48,49,66,79,139,140, 182,194–197].
7. DM2may potentiate in the brain AD-stimulating pathways that are
pertinent to dysfunction in blood-brain barrier, reactive oxygen
species, proteases, and leptin or other metabolism-regulatory
molecules [48,65,67,69,70,198–201].
8. Survival bias is an important potential confound that may lead to
artiﬁcially decreased diagnoses of DM2 and AD [202,203]. Persons
with DM2 are at increased risk to die of cardiovascular causes and
this risk renders them less likely to die of AD, all other things being
equal. This effectmay bias studies away from recognizing a positive
link between DM2 and AD (this does not explain why DM2
patients are found consistently to have higher risk for stroke,
however).
9. A number of rodent models including therapy-relevant strategies
show linkage between DM2-related effects on the rodent brain and
AD-relevant pathways [65,66,69,199,204,205].Fig. 4. Diabetes Case 2—87-year old male with dementia and predominantly cerebro
patient. Note that the MRI was obtained prior to a signiﬁcant decrease in the patient
vacuo and extensive pathological white matter enhancement. The red box in C show
white matter of visual cortex away from the ventricle. This vascular proﬁle shows e
new small blood vessels (arrow). E shows the area immediately subjacent to the ve
bars=150 μm in D and 300 μm in E.7.2.2. Data/hypotheses that suggest that AD is not linked speciﬁcally to
DM2
1. Numerous epidemiological and clinical–pathological studies have
reported that risk for decreased cognition in DM2 patients is not
mediated through AD, but through cerebrovascular disease instead
[13,14,47,153,206–216].
2. Confounds related to the metabolic syndrome (hypertension,
dyslipidemia, smoking, obesity, genetic factors, and inﬂammatory
mechanisms) also favor brain infarctions, so DM2 may be a strong
surrogate for stroke risk and/or low socioeconomic status
[8,9,142,143,152,217–220].
3. Most published neuroimaging ﬁndings in DM2 are apparently
referent to cerebrovascular disease [90,95–99,144,221,222].
4. Whatever the mechanism of DM2-related cognitive decline, the
presence of that additive dysfunction in someone developing AD
would “lower the threshold” to detection, independent of a speciﬁc
contribution by DM2. This phenomenon was previously demon-
strated in AD pathology [223]. This may help explain epidemio-
logical data linking DM2 to AD.
5. If hyperglycemia and/or poor glycemic control induces AD, then
longer-lived juvenile-onset diabetes might be expected to lead tovascular disease by pathology. A shows a chart that depicts the MMSE scores by this
's MMSE score (ﬁnal score=21). B and C show MRI scans that show hydrocephalus ex
s the area depicted in photomicrographs D and E. D shows a small blood vessel in the
xpansion of the Virchow–Robin space with organizing cellular material that includes
ntricle with frank necrosis (vertical arrow) and calciﬁcation (horizontal arrow). Scale
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that juvenile-onset diabetes patients do not show hippocampal
atrophy [224,225].
6. Whereas advanced glycation products are increased in AD brains,
there is not compelling evidence for these markers being elevated
in the brains of human DM2 patients [196].
7. To date, no therapies have been described in humans connected to
the hypothesis of DM2–AD link that have worked independently of
stroke risk.
8. In a microenvironment with abundant neuronal death and
secondary changes such as the AD brain, there are intuitively
good reasons for there to be associations, irrespective of DM2,
with deﬁcits in blood-brain barrier, reactive oxygen species,
advanced glycation end-products and other inﬂammatory mole-
cules, and other biochemical perturbations.
9. Findings in cell culture and rodent models must be scrutinized
critically before relevance to the aged human brain – much less to
AD pathology – is accepted.Fig. 5. Diabetes Case 3—81-year old female with mild cognitive impairment and with predo
infarctions in the frontal cortices (arrow in A) and the subtle hippocampal atrophy (B). Histo
hippocampal histopathology. In this patient, there were blood vessel proﬁles with expanded
and areas of white matter rarefaction in the ﬁmbria fornix (D), however, Alzheimer's-type
250 μm in D.8. The UK ADC experience: a retrospective case–control study from
an autopsy convenience sample stratiﬁed by identiﬁed diagnosis
of diabetes, and photomicrographs showing histopathology from
select diabetic and non-diabetic cases with clinical–radiographical
correlation
8.1. Rationale
8.1.1. Database analyses
Analysis of data about volunteers in a UK ADC research cohort may
provide evidence relevant to the controversy about the hypothetical
associations between DM2 and cerebrovascular or AD pathology. Our
autopsy series includes a group of longitudinally followed individuals
who were recruited while non-demented and followed for years. The
UK ADC database can be queried to indicate the clinical and
pathological indices are associated with DM2 before the advent of
severe, debilitating dementia. We hypothesized that pathology in
patients with DM2 would reﬂect their differential vulnerabilities to
cerebrovascular disease and/or to AD-type pathology.minantly cerebrovascular pathology (ﬁnal MMSE score=29). (A and B) MRIs show the
pathology conﬁrmed the presence of frontal cortex infarcts (not shown). C and D show
Virchow–Robin spaces with many corpora amylacea (C) and there were small infarcts
pathology in CA1 of the hippocampus was mild (not shown). Scale bar=150 μm in C,
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Few recent studies have described histopathological features in
aged diabetics' brains. Some pathological–radiographical studies exist
on small-vessel brain disease [226–235], but are not related to
diabetes per se. We performed this preliminary experiment in the
context of the UK ADC older adult research cohort. These studies
include participants who underwent premortem MRI scans to enable
radiographical–pathological correlation. This strategy may provide
the basis for developing novel hypotheses about mechanism(s) of
diabetic encephalopathy.
8.2. Methods: patients, assessments, neuropathology, and analyses
Research protocols were approved by the UK IRB. Details of
inclusion criteria and recruitment have been described previously
[223]. Patientswhohad come to autopsy fromtheUKnormalvolunteer
cohorts were the basis for the study (total N=234 patients), with
some patients excluded for a variety of factors including tumors, largeFig. 6. Diabetes Case 4—82-year old female diabetic patient with dementia and Alzheimer's d
obtained 4 years prior to the patient's demise. This already showed hippocampal atrophy (
Photomicrographs show the histopathological features from the red boxes. C depicts a sec
technique and shows severe involvement by Alzheimer's-type neuritic plaques (arrow) an
Alzheimer's disease” by pathology. In addition to the AD pathology, there was also some cere
the left parietal lobe (box in B) which shows an expanded Virchow–Robin space with organi
concomitant pathology is the rule and not the exception. Scale bars=150 μm in C, 100 μmcontusions, missing clinical data, etc., as described previously (N=95
excluded) [223]. These patients were relatively intact cognitively,
having been recruited as non-demented persons and followed for
years. Their pathology (if any) was presumed to represent the earlier
phases of cognitive decline. Only patients who had come to autopsy
with either “Yes” (N=50) or “No” (N=89) in the UK ADC database for
a diagnosis of diabetes were used (total N=139). These diagnoses
were derived from medical examinations during life, which included
blood evaluations, as well as from extensive evaluations of medical
charts as part of the UK ADC database management. Demographic
characteristics and particular clinical indices from these groups are
shown in Table 2. All initially normal individuals were contacted at 6-
month intervals, had detailed mental status testing, and had
neurological and physical examinations at least annually. Mental
status testing and neuropathological assessments were described in
detail previously [223]. Simple means were obtained from each group
for the clinical and pathological indices shown (Table 3). Signiﬁcance
was tested via Student's t test (unpaired, two-tailed).isease diagnosis during life (last MMSE score=19). A and B show the ﬁnal MRI that was
arrow in A) but also some periventricular white matter lesions (such as in arrow in B).
tion from CA1 ﬁeld of the hippocampus stained with the Gallyas silver impregnation
d many NFTs. This patient had Braak stage 6 and satisﬁed CERAD criteria for “Deﬁnite
brovascular disease including areas with rarefaction of white matter. D is a section from
zed cellular and acellular material. In an 82-year old patient such as this, some degree of
in D.
Fig. 7. Diabetes Case 5—75-year old male diabetic patient with no dementia and with subtle changes on MRI (last MMSE score 29). A shows the MRI with mild periventricular white
matter changes including some enhancement near in the subependymal basal ganglia. B depicts a photomicrograph from the same area, which includes pathology surrounding
medium-sized blood vessels with expanded Virchow–Robin spaces. Surrounding the vessels are many corpora amylacea and gliosis. Scale bar=150 μm.
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• Diabetes Case 1 (male) died at the age of 88 with history of
DM2. Last MMSE score was 26 out of a possible 30 (mild
cognitive decline).
• Diabetes Case 2 (male) died at the age of 87 with history of DM2.
Last MMSE score was 21 out of a possible 30 (moderate-to-severeFig. 8. Diabetes Case 6—72-year old female patient with poorly controlled diabetes (two
the hippocampal formation showed many corpora amylacea including in the cornu amm
effacement of the normal cytoarchitecture in association with the presence of many corpo
contained many corpora amylacea. By contrast, in Control Cases 1 and 2, there were few (
and D.cognitive decline). MRI was obtained within 4 months of patient's
death.
• Diabetes Case 3 (female) died at the age of 81 with history of DM2.
Last MMSE score was 29. MRI was obtained within a year before
patient's death.
• Diabetes Case 4 (female) died at age 82 with history of DM2 and
diagnosed clinically with AD. Last MMSE score was 19 (severeconﬁrmed readings in excess of 150 mg/dl) and mild cognitive decline. In this case,
onis subﬁelds. These are shown in the CA4/dentate gyrus area, where there is some
ra amylacea. B shows the crux of the inferior horn of the lateral ventricle, which also
arrow in C) or no corpora amylacea there. Scale bars: 300 μm in A and B, 150 μm in C
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death.
• Diabetes Case 5 (male) died at age 75 with history of DM2. Last
MMSE score was 28 (non-demented). MRI was obtained four years
before patient's death.
• Diabetic Case 6 (female) died at age 72 years with history of poorly
controlled DM2, last MMSE score 29 (non-demented).
• Control Case 1 (male) died at age 78 years with no history of
diabetes, last MMSE score of 28 (non-demented).
• Control Case 2 (male) died at age 99 years no history of diabetes
but with a history of hypertension, last MMSE score of 26 (mild
cognitive impairment).
8.3. Results
This retrospective case–control study from an autopsy convenience
sample includes patients that are relatively well matchedwith regard to
levels of formal education and ApoE alleles (Table 2). However, the
diabetics died at a slightly younger age (84 years versus 88 years,pb0.02
by two-tailed Student's t test), and tended to have a slightly higher ﬁnal
MMSE scores (26 versus 24, pb0.1 by two-tailed Student's t test). In
terms of pathological parameters, the diabetics tended to have more
small infarcts but a slightly less degree of AD-type lesions (Table 3). AD
lesions (NFTs andneuritic plaques) are directly quantiﬁedbycountingor
deﬁned according to Consortium to Establish a Registry for AD staging
and Braak staging, which are based on consensus criteria for staging AD
pathological severity [236,237] (Table 3).
Photomicrographs portray a spectrum of changes in these older
personswith differing cognitive changes. The photomicrographs show
hematoxylin and eosin (H and E)-stained sections with a special focus
on changes in blood vessels and white matter. Histology of cerebral
blood vessels and the surrounding Virchow–Robin spaces are shown
in Fig. 3 (from Control Case 1 and Diabetes Case 1). Fig. 4 depicts a
patient (Diabetes Case 2) with an MRI obtained just prior to a
signiﬁcant decline in cognition as reﬂected in a drop in MMSE scores
(down to 21 near death). In this patient, there weremoderate changes
referent to Alzheimer's pathology (Braak stage 3), but the predomi-
nant pathological changes were related to the cerebral vasculature. In
Diabetes Case 3 (Fig. 5), there were also cerebrovascular disease
changes including frank infarctions in the frontal cortices bilaterally.
There were small infarcts in the temporal lobe including the
hippocampal formation, where there was also minimal Alzheimer's-
type pathology. By contrast, in Diabetes Case 4 (Fig. 6), there was both
dementia clinically as well as advanced AD pathologically. Still, even in
this case, notable small-vessel cerebrovascular disease was present.
Diabetes Case 5 (Fig. 7) had no dementia, no Alzheimer-type
pathology, but had subtle white matter pathology including some
periventricular enhancement near the basal ganglia. The photomicro-
graph shows the corresponding region that contained expandedFig. 9. Research has provided insights into diabetes-related cognitive dysfunction. However,
the hypothesized anatomic substrates associated with “diabetic encephalopathy”. In turn, th
The dashed arrow and question mark at the bottom indicate the possibility that metabolic
anatomic pathology.Virchow–Robin spaces andmany corpora amylacea. In Diabetes Case 6
(Fig. 8), a patient with poorly controlled DM2 and mild cognitive
decline, there were many corpora amylacea within the cornu
ammonis of the hippocampal formation, as well as near the inferior
horn of the lateral ventricle.
8.4. Discussion
This study focused on persons who were recruited without
cognitive impairment and followed longitudinally in a research
clinic. This is an important strength of the study because long-term
medical and neuropsychological studies could be performed on each
patient. It also allowed us to minimize various recruitment biases
related to already-demented subjects. However, there are several
caveats that are germane to these data. Most importantly, the degree
of glycemic control was not thoroughly documented by an
endocrinologist in all patients. This is only a study of the association
of a clinical diagnosis of diabetes, rather than an association that is
related to glycemic control per se. The importance of the age
difference (average age at death 84 for diabetics, 88 for non-
diabetics, pb0.02) may constitute an important confound to this
analysis. However, note that the cerebrovascular pathology, despite
the age difference, was more severe in the diabetics. There are other
trends, including a trend to increased hypertension, in the diabetics
that may be contributory to the different prevalence of cerebrovas-
cular disease. In summary, results from our database are in agreement
with prior studies indicating thatDM2 is associatedwith increased risk
for cerebrovascular disease, and yet there is no positive association
between the diagnosis of DM2 and the development of AD pathology
[13,14,47,153,206–216].
We also performed a study of a subset of patients including
pathological–radiographical correlation. This preliminary, descriptive
study underscores our impression from the research literature:
cerebrovascular pathology, including extensive small-vessel disease,
is an important component of CNDM2. This type of pathology can exist
in relative isolation, or together with other diseases such as AD. It is
hoped that the pathological–radiographical correlationwill help some
clinicians to “visualize” at a cellular and sub-cellular level the
radiographical changes that have been recorded in the brains of
DM2 patients.
In this limited sample, there were relatively many corpora
amylacea in the brains of the diabetic patients. By contrast, in the
non-diabetics (Control Case 1 and Case 2) there were few or no
corpora amylacea in this location. The presence of corporal amylacea
in the brains of older patients is generally considered a nonspeciﬁc
sign of tissue damage or cell loss. However, since these lesions are
indeed aberrant, ubiquitinated intracellular deposits of glycated
material [238,239], it is possible that their presence in the brains of
diabetics may have speciﬁc and pathogenetic implications.the speciﬁcs are unclear about how the chemical perturbations of diabetes correlate to
e contribution to cognitive changes from the pathological lesions is poorly understood.
perturbations in diabetes may produce cognitive changes in the absence of detectable
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make comparative assessments. They offer a preliminary, and purely
descriptive, portrayal of some of the histopathological features in a
limited subset of patients with DM2. However, we hope that these
photomicrographs may help demonstrate the potential value of
evaluating the histopathological features in human brains with well-
documented antemortem characteristics.
9. Summary and conclusions
In the absence of a known pathognomonic anatomic substrate for
cognitive dysfunction in diabetics, the question arises—perhaps there
are no deﬁnitive histopathological changes in diabetic brains? Many
metabolic disorders induce mental changes, or delirium, out of
proportion to known neuropathological changes [240,241]. Such
may be induced by ﬂuxes in blood levels of insulin, glucose, and
other metabolic parameters in DM2. Other diseases such as hypoxia
can produce brain atrophy and cell death in the absence of a
pathognomonic change [85,128]. Hence, delirium or a disease with
entirely nonspeciﬁc pathology may partly contribute to diabetic
encephalopathy.
With the above caveat about the speciﬁcity of CNDM2, several
associations between DM2 and brain pathology appear to exist
(Fig. 9). Neuropsychological studies have indicated that there is
enduring cognitive deﬁcits in DM2 patients. There is compelling
evidence from neuroimaging studies in humans that there are
changes in brain parenchyma that are present disproportionately in
the brains of diabetics. The speciﬁcity of these changes cannot be
reliably ruled out because relatively few studies have tackled the
histopathology of diabetes in the brain over the past few decades.
This is unfortunate because the changing times have produced new
tools available to neuropathologists. There is also increased pre-
valence of DM2 in Western populations [1] and it would be helpful
to evaluate brains in the context of current trends in comorbidities
and treatments.
As with many other past studies, we are unable to supply new and
deﬁnitive answers about CNDM2 based on our illustrative cases and
analyses. It is somewhat surprising that there have been so few studies
speciﬁcally addressing the neuropathology of small-vessel disease in
DM2. Moreover, a few questions may be worthy of being addressed.
These questions derive from a synthesis of the known scientiﬁc
literature and the preliminary and descriptive studies that are
presented above.
○ Are corpora amylacea really benign and/or nonspeciﬁc in DM2
brains? Perhaps these structures, comprising glycated material
[130,239], may cause or reﬂect a more speciﬁc disease process than
previously thought. Corpora amylacea have previously been noted
in the context of brain pathology [238,242–244], but not correlated
to the diagnosis of diabetes per se.
○ Are there speciﬁc markers for microangiopathy in DM2?
○ Is there a speciﬁc process involving Virchow–Robin spaces in DM2?
○ Why do the results of studies about the relationship between AD
and DM2 vary so much?
Future studies are needed to address these and the other many
outstanding questions regarding CNDM2. This ﬁeld is increasingly
topical as the number of DM2 patients increase, and as the average age
and longevities of Western populations increase. Many experimental
systems should be brought to bear in studying this widespread
disease, including the direct evaluation of human brain tissue.
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